Mersana Therapeutics (NASDAQ:MRSN) is set to release its earnings data before the market opens on Thursday, August 8th. Analysts expect Mersana Therapeutics to post earnings of ($0.38) per share for the quarter.
Mersana Therapeutics (NASDAQ:MRSN) last posted its earnings results on Thursday, May 9th. The company reported $0.70 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.73. The business had revenue of $41.04 million during the quarter, compared to analyst estimates of $30.11 million. Mersana Therapeutics had a negative return on equity of 57.49% and a negative net margin of 61.68%. On average, analysts expect Mersana Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of Mersana Therapeutics stock traded up $0.08 on Friday, reaching $3.58. The company’s stock had a trading volume of 102,658 shares, compared to its average volume of 148,065. The company has a market cap of $171.30 million, a P/E ratio of -1.28 and a beta of 1.38. The company’s fifty day moving average price is $3.97. Mersana Therapeutics has a 52 week low of $2.85 and a 52 week high of $15.93. The company has a quick ratio of 6.24, a current ratio of 6.24 and a debt-to-equity ratio of 0.02.
A number of research firms have commented on MRSN. Cowen reissued a “buy” rating on shares of Mersana Therapeutics in a report on Sunday, June 2nd. Zacks Investment Research upgraded Mersana Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research note on Wednesday, July 10th. Finally, ValuEngine upgraded Mersana Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Mersana Therapeutics currently has a consensus rating of “Buy” and an average target price of $11.63.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Further Reading: Market Capitalization and Individual Investors
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.